apposters.com
Global Public Offering Fund
Edit

Global Public Offering Fund

https://www.gpofund.com
Last activity: 18.04.2024
Active
The Global Public Offering Fund (GPO Fund) is a growth equity fund investing in founder-led, pre-IPO technology companies that can benefit from access to global capital markets. The fund primarily invests in North American venture-backed, transformative tech-enabled companies that can accelerate growth and market dominance by pursuing global capital investment and a cross-border public listing on a major APAC exchange.
The GPO Fund targets investment opportunities that can substantially benefit from:
+ Going public globally within 12-18 months,
+ Improved ability to attract and retain talent,
+ Gaining the support of a global syndicate of investors,
+ Operational expansion, especially in fast-growing Asia-Pacific,
+ Simplification of the capital structure and public price discovery,
+ Ongoing access to capital markets to finance growth, M&A and working capital,
+ Enhanced credibility, liquidity and flexibility achieved as a publicly listed company.
Mentions
120
Location: United States, New York
Employees: 1-10
Founded date: 2018

Mentions in press and media 120

DateTitleDescription
18.04.2024PainReform Announces Closing of $4 Million Public Offering-
17.04.2024TScan Therapeutics Announces Pricing of Upsized $150 Million Public OfferingWALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment...
17.04.2024TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering-
16.04.2024Silver Mountain Announces $7.5 Million Public Offering-
16.04.2024TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering-
12.04.2024Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public OfferingSAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 pe...
11.04.2024Longeveron Announces Closing of $5.2 Million Public OfferingMIAMI, April 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as...
11.04.2024Longeveron Announces Closing of $5.2 Million Public Offering-
11.04.2024Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering-
08.04.2024i-80 Announces C$86 Million Bought Deal Public Offering of Units-
Show more

Reviews 0

Sign up to leave a review

Sign up Log In